CARRA December 2020 Newsletter - Issue 1



CARRA Annual Scientific Meeting is Going Virtual for 2021!

Save the Dates: April 16-17, 2021

After careful consideration, CARRA has made the decision to move our next Annual Scientific Meeting from an in-person to an all-virtual meeting. The meeting will be held from 11am - 3pm Eastern on Friday April 16 and from 11am - 3:15pm Eastern on Saturday April 17. This two-day meeting will feature engaging plenary speakers and topics relevant to the rheumatology community, virtual networking opportunities with exhibitors and attendees, and the latest updates from CARRA and the Steering Committee. The Fellow session, Patient/Caregiver Orientation session and Disease Committee Kick-Off meetings will be held in January. CARRA workgroup virtual meetings will be held in February and March. We are also working closely with PRSYM on abstract collaboration. Please save the dates and stay tuned to our website for more details in the coming weeks!

Renew Your CARRA Membership for 2021 Today!

Membership Renewal Due Date: February 1, 2020

As a CARRA member, you can:

  • Receive travel support to attend the Annual Scientific Meeting
    • *The 2021 Annual Scientific Meeting will be held virtually  
  • Access the new CARRA Membership Directory (see below)!

New in 2021: Membership Directory!

  • After the renewal process, members will be asked to complete their member profile for the new membership directory.
  • The goal is to help members find and connect with one another based on areas of research interest, professional goals, location and other searchable fields.  
  • The directory is available here.

A few reminders on renewing your membership:

  • Please review and update (if necessary) your primary research group (e.g., Cross Cutting, JDM, JIA, Pain, Rare Diseases, SLE, TRTC). Members of TRTC or Pain may select two primary research groups.
  • Please review and update your current workgroups. Members interested in joining a workgroup should contact the workgroup leader or the appropriate disease/research committee chair. Visit the CARRA website for more information on CARRA research committees and workgroups.

CARRA members are expected to participate in surveys and elections and renew their membership annually to remain in good standing.

Click here to renew your membership today!

New CARRA Board Members in 2020

Please welcome Stacy Ardoin, MD (CARRA Treasurer), Daniel H. Solomon, MD, MPH, and John Sundy, MD, PhD to CARRA’s Board of Directors!

Stacy Ardoin serves on CARRA’s Executive Committee of the Board as CARRA Treasurer. She is a pediatric and adult rheumatologist with more than 20 years of experience and is the Chair of Rheumatology at Nationwide Children’s Hospital. As a clinician and clinician research scientist in adult and pediatric rheumatology, her research centers on the transition from pediatric to adult care and on the long-term complications of adult and childhood lupus. She previously served as the elected SLE Committee Chair for CARRA from 2015 to 2018.

“I have been an active CARRA member since I started my internal medicine/pediatrics rheumatology fellowship in 2002, and it has been inspiring to see how CARRA has grown and matured into a large, dynamic research organization representing the vast majority of North American pediatric rheumatologists.”

Daniel Solomon is an adult rheumatologist and Professor of Medicine and Chief of the Section Clinical Sciences in the Division of Rheumatology at Brigham and Women’s Hospital (BWH). He holds the Matthew H. Liang Distinguished Chair in Arthritis and Population Health at BWH. His early work focused on the safety of NSAIDs and selective COX-2 inhibitors, and he continues to study analgesics. Solomon’s current research focuses on cardiovascular disease in rheumatoid arthritis, and he is the co-Principal Investigator on an NIH funded trial testing the effect of disease-modifying antirheumatic drugs (DMARDs) on cardiovascular disease, also known as the TARGET trial. He also has several ongoing projects improving implementation of treat to target in rheumatoid arthritis.

Dr. Solomon has worked with CARRA for years on a variety of comparative effectiveness issues as well as collaborating on training fellows through the VERITY P30 funded course. He has been an invited speaker at the CARRA Annual Scientific Meeting on multiple occasions and previously served as a consultant on CARRA’s “GO Grant”.

John Sundy is an adult rheumatologist and immunologist with over 25 years of academic and industry experience developing therapies for inflammatory and fibrotic diseases. His research has focused on translational research and clinical trials of novel therapies for a broad variety of immunologic and inflammatory diseases. Dr. Sundy is currently the Chief Medical Officer at Pandion Therapeutics where he leads the clinical development of innovative modular biologic medicines targeting severe inflammatory and autoimmune diseases. Dr. Sundy previously served as Senior Vice President and Inflammation Therapeutic Area Head at Gilead Sciences, where he was responsible for Phase 1-4 development of over a dozen novel therapeutics, including completion of Phase 3 trials for the JAK inhibitor filgotinib filed worldwide in RA. He also was an Associate Professor of Medicine with tenure at Duke University and the Duke-National University of Singapore Graduate Medical School. At Duke he held several leadership roles including Associate Director of the Duke Clinical Research Institute (DCRI) and Director of Duke's Global Proof of Concept Research Unit Network.

He has longstanding affinity for CARRA having been involved with the organization at the time

that initial NIAMS funding for the CARRA Legacy Registry was awarded. Working in collaboration with Drs. Schanberg, Sandborg, Wallace and Kimura he gained an appreciation for the particular challenges that pediatric rheumatologists face in both clinical practice and in research. “

He is currently an Adjunct Professor of Medicine at Duke University, and has been board certified in Internal Medicine, Rheumatology and Allergy/Immunology.

“What has been remarkable to me is the cooperation and dedication that pediatric rheumatology community has demonstrated in coalescing around CARRA. Having devoted most of my academic and industry research efforts to novel therapeutics, I am interested in contributing to the CARRA mission by facilitating access to research for children with rheumatologic diseases.”

CARRA Elections – Round 2 Starting Soon!

Voting for Round 1 of the CARRA Elections, which included the positions of JDM Chair, SLE Chair, and Small Centers Chair has closed. Congratulations to these newly elected chairs!

JDM Committee Chair: Susan Kim, MD, MMS

SLE Committee Chair: Andrea Knight, MD, MSCE

Small Centers Committee Chair: Sheetal Vora, MD

Round 2 Nominations will be open until December 18 for the following Steering Committee Positions:

1Position receives 5% salary support

For more information about open positions, visit the elections page of the CARRA website

Arthritis Foundation Updates

Introducing the Live Yes! JA Insights Program!

This new research assessment tool uniquely captures the experiences and challenges of what everyday life is like living with juvenile arthritis and related childhood rheumatic conditions. Input from parents of children ages 5-17 helps the Arthritis Foundation plan research, and develop new resources and customized local programming. By participating in this research, parents can contribute to knowledge that may help their child better navigate life with arthritis and contribute to a brighter future for all JA kids. The Arthritis Foundation worked with The Dartmouth Institute Community and Family Medicine, Center for Program Design & Evaluation to develop our JA Insights program. The development process included stakeholder interviews, literature review, Modified Delphi & Nominal Group Technique and Focus Groups. Included interviews with JA parents, Pediatric Rheumatologists and focus groups with parents and teens. The JA Insights assessment is comprised of PROMIS-Pedi 25 Parent Proxy (Physical Health & Social/Emotional Health domains) and the Patient Self Advocacy Scale (PSAS) (Experience of Care). Please encourage your parents and patients to sign up and participate. For more information, visit

Important Dates and Deadlines